



PRESS RELEASE

MolMed: Publication of the Minutes of the Ordinary Shareholders Meeting held on April 27th 2020

Milan (Italy), May 18th 2020 – MolMed S.p.A. (MLMD.MI) (the “Company”), a biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases informs that the Minutes of the Ordinary Shareholders Meeting held on April 27th 2020 is available (in Italian) to the public at the Company registered office, on the Company website (www.molmed.com) in the page dedicated to the Shareholders Meeting held on April 27th 2020 – section Investors/ Shareholders Meeting - and on the authorized storage device 1Info-Storage (www.1info.it).

This press release is available on the company’s website <http://www.molmed.com>

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed is the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies ex vivo for its proprietary products as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed’s is also developing its CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso. For more information please visit www.molmed.com.

For further information:

Molmed S.p.A.

Investor Relations & Communication Department

MolMed S.p.A.
+39 02 21277.205
investor.relations@molmed.com

Tommasina Cazzato

Press Office
Community Group
+39 345 7357751
tommasina.cazzato@communitygroup.it